Polymorphic forms of alcaftadine
The present invention relates to novel polymorphic forms of alcaftadine, processes of preparing novel polymorphic forms of alcaftadine and pharmaceutical compositions thereof.
1. A β-crystalline form of alcaftadine having characteristics of X-ray diffraction peaks at 10.0, 11.4, 12.0, 15.5, 16.2, 18.4, 19.6, 20.2, 20.5, 22.0, 23.1, 23.5, 24.6, 25.4, 25.8, 28.8, 31.3±0.2 degrees 2θ.
2. A β-crystalline form of alcaftadine characterized by having substantially the same X-ray diffraction pattern as depicted in FIG. 3 .
3. A β-crystalline form of alcaftadine characterized by having substantially the same infrared spectrum as depicted in FIG. 4 .
4. A process of preparing a β-crystalline form of alcaftadine, the process comprising the steps of:
a) suspending crude alcaftadine in an organic solvent to obtain a suspension;
b) stirring the suspension obtained in the step of suspending crude alcaftadine; and
c) isolating a β-crystalline form of alcaftadine.
5. The process according to claim 4 , wherein the suspension obtained in the step of suspending crude alcaftadine was stirred at a temperature in the range of 0° C. to 50° C. for a period of 30 minutes to 8 hours.
6. The process according to claim 4 , wherein the organic solvent is an ether solvent selected from the group consisting of tetrahydrofuran, dioxane, diethyl ether, diisopropyl ether, dibutyl ether, methyl tertiary butyl ether, methyl ethyl ether, methyl isobutyl ether and mixture(s) thereof.
7. The process according to claim 4 , wherein the β-crystalline form of alcaftadine is isolated by the steps of filtration, centrifugation, washing, drying or combinations thereof.
8. The process according to claim 7 , wherein the isolated β-crystalline form of alcaftadine is dried at a temperature in the range of 40° C. to 110° C. for a period of 2 hours to 12 hours under reduced pressure.